Drug-resistant infections aren't just a health crisis — they're an economic one. New research presented at IDWeek 2026 estimates that antimicrobial resistance (AMR) was linked to $3.5 trillion in global economic losses in 2021, with $835 billion directly caused by drug-resistant bacteria. Sub-Saharan Africa bore the heaviest proportional burden, but researchers warn no country is safe — resistant bacteria don't carry passports.
Drug-resistant infections aren't just a health crisis — they're an economic one. New research presented at IDWeek 2026 estimates that antimicrobial resistance (AMR) was linked to $3.5 trillion in global economic losses in 2021, equivalent to 2.25% of global GDP. Of that, $835 billion was directly caused by drug-resistant bacteria — roughly $106 per person on Earth. Researchers used disability-adjusted life years (DALYs) from the Global Burden of Disease dataset and applied a "value of lost welfare" framework to translate human suffering into economic terms that budget makers can act on.
Bloodstream and lower respiratory infections drove 74% of the directly attributable losses, with six pathogens — Klebsiella pneumoniae, S. pneumoniae, Acinetobacter baumannii, E. coli, S. aureus, and Pseudomonas aeruginosa — leading the charge. While South Asia, East Asia, and North America saw the largest absolute losses, sub-Saharan Africa suffered the greatest hit relative to GDP.
By the Numbers:
Why it matters: AMR is already killing over a million people a year, but this study reframes the crisis in dollars — a language that moves policy. Researchers say targeted investments in vaccines (like pneumococcal conjugate vaccines), diagnostics, stewardship, and antibiotic access in low-resource settings could curb these losses before resistant strains spread further across borders.
